One Million Syringes of RADIESSE(r) Dermal Filler Have Been Shipped

RADIESSE Dermal Filler Has Become One of the Leading Dermal Fillers Worldwide

SAN MATEO, Calif. and PARIS, Jan. 8, 2009 (GLOBE NEWSWIRE) -- BioForm Medical,
Inc. (Nasdaq:BFRM) today announced, at a presentation at the 11th Annual
Meeting of the International Master Course on Aging Skin (IMCAS), that it has
shipped more than 1,000,000 syringes of RADIESSE(r) dermal filler worldwide
since 2002. RADIESSE dermal filler has been available since 2002 for aesthetic
uses in the Europe and for reconstructive and therapeutic uses in the United
States. In 2006, BioForm Medical received U.S. Food and Drug Administration
approval of RADIESSE dermal filler for facial aesthetics applications, and use
of this product has rapidly expanded. RADIESSE dermal filler has demonstrated
an excellent safety profile, comparable to short term hyaluronic acid products.
RADIESSE dermal filler is also the only dermal filler to have demonstrated, in
peer-reviewed studies, better aesthetic correction and higher patient
satisfaction than Restylane(r) and Juvederm(r). 

As of December 2008, BioForm Medical has supplied more than 1,000,000 syringes
of RADIESSE dermal filler to approximately 10,000 medical and aesthetics
practices worldwide. With the rapid adoption of this product, RADIESSE dermal
filler has become one of the leading dermal fillers in the worldwide market.
BioForm Medical believes that to date, RADIESSE dermal filler is the only
dermal filler, other than collagen and hyaluronic acid, to reach this 1,000,000
syringe milestone. 

Industry-Leading Peer Reviewed Publications with RADIESSE Dermal Filler

More than 60 published peer-reviewed scientific articles have demonstrated the
utility of RADIESSE dermal filler. The studies and clinical publications
collectively reporting on several-thousand-patient experience with RADIESSE
dermal filler include: 

 * 117-patient comparative study vs. Cosmoplast (human collagen) by Dr.
   Stacy Smith, Dr. Mariano Busso, Dr. Marla McClaren and Dr. Lawrence
   Bass published in the Journal of Dermatologic Surgery in December
   2007, which supported FDA approval for fold and wrinkle treatment,
   showed superior performance of RADIESSE dermal filler vs.
   Cosmoplast on nearly every measure evaluated
 * 60-patient split-face, blinded comparative study vs. Restylane by
   Dr. Marion Moers-Carpi and Dr. Jaime Tufet published in the Journal
   of Dermatologic Surgery in February 2008, which demonstrated more
   patients improved at 6 months and 9 months following treatment with
   RADIESSE dermal filler than with Restylane, and higher patient
   satisfaction with RADIESSE dermal filler than with Restylane
 * 205-patient randomized, blinded comparative study vs. Juvederm and
   Perlane by Dr. Marion Moers-Carpi, Dr. Stephan Vogt, Dr. Begonia
   Santos, Dr. Jorge Planas, Dr. Sonia Vallve and David Howell, PhD
   published in the Journal of Dermatologic Surgery in December 2007,
   which demonstrated higher patient satisfaction and greater
   likelihood of patients to return if treated with RADIESSE dermal
   filler compared with Juvederm or Perlane
 * 100-patient study treating patients with HIV-associated lipoatrophy
   by Dr. Stacey Silvers, Dr. Joseph Eviatar, Dr. Michael Echavez and
   Dr. Alexandra Pappas that demonstrated safety of treatment with up
   to 15 syringes of RADIESSE dermal filler, which was published in
   the Plastic and Reconstructive Surgery Journal in September 2006
 * 1,000-patient clinical report of 4-year follow-up with RADIESSE
   dermal filler by Dr. Thomas Tzikas published in the Journal of
   Dermatologic Surgery in June 2008
 * 58-patient radiographic and computed tomographic imaging study of
   RADIESSE dermal filler in nasolabial fold and HIV-associated
   lipoatrophy treatment by Dr. Alastair Carruthers, Dr. Jean
   Carruthers, Dr. Marc Liebeskind and Dr. Bruce Forster published in
   the Journal of Dermatologic Surgery in June 2008
 * 24-patient, 26-month clinical report on nasal augmentation with
   RADIESSE dermal filler by Dr. Hilton Becker published in the
   Plastic and Reconstructive Surgery Journal in June 2008
 * 5-patient clinical report to characterize new collagen formation
   following RADIESSE dermal filler treatment by Dr. Alexander Berlin,
   Dr. Mussarratt Hussain and Dr. David Goldberg published in the
   Journal of Dermatologic Surgery in June 2008
 * An investigation of physical properties when RADIESSE dermal filler
   is mixed with lidocaine by Dr. Mariano Busso published in the
   Journal of Dermatologic Surgery in June 2008
 * 19-patient clinical report on the use of RADIESSE dermal filler for
   mid-face volume loss by Dr. Kenneth Beer, Monica Yohn, RN and Dr.
   Joel Cohen published in the Journal of Drugs in Dermatology in
   April 2008
 * 14-patient clinical report on nonsurgical rhinoplasty with RADIESSE
   dermal filler by Dr. Cameron Rokhsar and Dr. David Ciocon published
   in the Journal of Dermatologic Surgery in April 2008
 * 113-patient clinical report on patient satisfaction outcomes with
   RADIESSE dermal filler from three physicians' practices by Dr. Neil
   Sadick, Dr. Bruce Katz and Dr. Deborshi Roy published in the
   Journal of Dermatologic Surgery in December 2007
 * A clinical report on the use of RADIESSE dermal filler in hand
   augmentation by Dr. Mariano Busso and Dr. David Applebaum published
   in the Journal of Dermatologic Therapy in November 2007
 * 13-patient clinical report on the use of RADIESSE dermal filler for
   the correction of post-rhinoplasty contour deficiencies by Dr.
   Howard  Stupak, Dr. Thomas Moulthrop, Patricia Wheatley, RN,
   Allison Tauman, PharmD, and Dr. Calvin Johnson published in the
   Archives of Facial Plastic Surgery in March 2007
 * 22-patient, 12-18 month clinical report on the use of RADIESSE
   dermal filler for the correction of nasolabial fold depressions by
   Dr. Murad Alam and Dr. Simon Yoo published in the Journal of the
   American Academy of Dermatology in February 2007
 * 139-patient clinical report on the use of RADIESSE dermal filler in
   multiple aesthetic indications by Dr. Silvia Cuevas, Dr. Maria
   Patricia Rivas, Dr. Sadegh Amini and Dr. Eduardo Weiss published in
   the American Journal of Cosmetic Surgery in October 2006
 * 609-patient clinical report on the use of RADIESSE dermal filler in
   multiple aesthetic indications by Dr. David Jansen and Dr. Miles
   Graivier published in the Plastic and Reconstructive Surgery
   Journal in September 2006
 * 40-patient, 18-month clinical report on the use of RADIESSE dermal
   filler by Dr. Patricio Jacovella, Dr. Claudia Peiretti, Dr. Diego
   Cunille, Dr. Mauricio Salzamendi and Dr. Sophia Asiu Schechtel
   published in the Plastic and Reconstructive Surgery Journal in
   September 2006

About RADIESSE Dermal Filler:

RADIESSE dermal filler is approved in the United States for the correction of
moderate to severe facial folds and wrinkles, including nasolabial folds and
for restoration and/or correction of the signs of facial fat loss (lipoatrophy)
in people with HIV. In Europe, RADIESSE dermal filler is CE-marked for plastic
and reconstructive surgery, including deep and sub-dermal soft tissue
augmentation of the facial area. We believe that the general advantages of
RADIESSE dermal filler that have enabled the rapid uptake of the product
include: excellent initial correction, durability of treatment of one year or
longer in many patients, and the physical characteristics of holding shape and
lifting tissues better than some filler materials. Procedural side effects from
RADIESSE dermal filler injection are consistent with side effects commonly
associated with injectable dermal filler treatments, and may include bruising,
swelling, redness, pain, and itching. In most cases, these side effects go away
within two weeks following treatment. There have been no reported long term
adverse effects of RADIESSE dermal filler in the pivotal clinical studies
conducted, and there have been no reports of delayed onset adverse events in
these clinical studies. 

About BioForm Medical, Inc.:

BioForm Medical, Inc. is a medical aesthetics company headquartered in San
Mateo, California, developing products that enhance aesthetic procedures
performed in dermatology and plastic surgery practices. BioForm Medical's lead
product is RADIESSE(r) dermal filler, a long-lasting filler for use in facial
aesthetics. BioForm Medical is developing several future aesthetics products,
including a radiofrequency treatment to reduce nerve function in the forehead,
a sclerotherapy treatment for spider veins, and a surgical adhesive for brow
lifts. For more information about BioForm Medical, please visit
www.bioform.com. 

RADIESSE(r) is a registered trademark of BioForm Medical, Inc.  Restylane(r) is
a registered trademark of HA North American Sales AB, a subsidiary of Medicis
Pharmaceutical Corporation. 

Juvederm(r) mark owned by Allergan Industrie SAS.

CONTACT:  BioForm Medical, Inc.
          Adam Gridley, Senior Vice President, Corporate Development
          650.286.4025